Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF’s RW efficacy and safety in Italian UC patients. Research design and methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of TOF. Results: We enrolled 166 patients with a median follow-up of 24 (IQR 8–36) weeks. Clinical remission was achieved in 61/166 (36.7%) and 75/166 (45.2%) patients at 8-week and 24-week follow-ups, respectively. The optimization was requested in 27 (16.3%) patients. Clinical remission was achieved more frequently when TOF was used as a first/second line rather than a third/fourth line treatment (p = 0.007). Mucosal healing was reported in 46% of patients at the median follow-up time. Colectomy occurred in 8 (4.8%) patients. Adverse events occurred in 12 (5.4%) patients and severe in 3 (1.8%). One case of simple Herpes Zoster and one of renal vein thrombosis were recorded. Conclusions: Our RW data confirm that TOF is effective and safe in UC patients. It performs remarkably better when used as the first/second line of treatment.

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study / Tursi, A.; Mocci, G.; Cingolani, L.; Savarino, E.; Pica, R.; Cocco, A.; Zippi, M.; Napolitano, D.; Schiavoni, E.; Pugliese, D.; Scaldaferri, F.; Costa, F.; Marzo, M.; Serio, M.; Scarcelli, A.; Bolognini, L.; Bendia, E.; Maconi, G.; Cannatelli, R.; Piergallini, S.; Bodini, G.; Calabrese, F.; Ferronato, A.; Pranzo, G.; Elisei, W.; Monterubbianesi, R.; Faggiani, R.; Rodino, S.; Sebkova, L.; Grossi, L.; Gaiani, F.; de Angelis, G.; Lorenzetti, R.; Allegretta, L.; Cazzato, A. I.; Scorza, S.; Della Valle, N.; Sacco, R.; Forti, G.; Colucci, R.; Tonti, P.; Neve, V.; Rocco, G.; Sacchi, C.; Zampaletta, C.; Pagnini, C.; Graziani, M. G.; Di Paolo, M. C.; Onidi, F. M.; Usai Satta, P.; Picchio, M.; Papa, A.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - (2023), pp. 1-8. [10.1080/14656566.2023.2230126]

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Gaiani F.;de Angelis G.;
2023-01-01

Abstract

Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF’s RW efficacy and safety in Italian UC patients. Research design and methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score. The primary endpoints were to evaluate the effectiveness and safety of TOF. Results: We enrolled 166 patients with a median follow-up of 24 (IQR 8–36) weeks. Clinical remission was achieved in 61/166 (36.7%) and 75/166 (45.2%) patients at 8-week and 24-week follow-ups, respectively. The optimization was requested in 27 (16.3%) patients. Clinical remission was achieved more frequently when TOF was used as a first/second line rather than a third/fourth line treatment (p = 0.007). Mucosal healing was reported in 46% of patients at the median follow-up time. Colectomy occurred in 8 (4.8%) patients. Adverse events occurred in 12 (5.4%) patients and severe in 3 (1.8%). One case of simple Herpes Zoster and one of renal vein thrombosis were recorded. Conclusions: Our RW data confirm that TOF is effective and safe in UC patients. It performs remarkably better when used as the first/second line of treatment.
2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study / Tursi, A.; Mocci, G.; Cingolani, L.; Savarino, E.; Pica, R.; Cocco, A.; Zippi, M.; Napolitano, D.; Schiavoni, E.; Pugliese, D.; Scaldaferri, F.; Costa, F.; Marzo, M.; Serio, M.; Scarcelli, A.; Bolognini, L.; Bendia, E.; Maconi, G.; Cannatelli, R.; Piergallini, S.; Bodini, G.; Calabrese, F.; Ferronato, A.; Pranzo, G.; Elisei, W.; Monterubbianesi, R.; Faggiani, R.; Rodino, S.; Sebkova, L.; Grossi, L.; Gaiani, F.; de Angelis, G.; Lorenzetti, R.; Allegretta, L.; Cazzato, A. I.; Scorza, S.; Della Valle, N.; Sacco, R.; Forti, G.; Colucci, R.; Tonti, P.; Neve, V.; Rocco, G.; Sacchi, C.; Zampaletta, C.; Pagnini, C.; Graziani, M. G.; Di Paolo, M. C.; Onidi, F. M.; Usai Satta, P.; Picchio, M.; Papa, A.. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - (2023), pp. 1-8. [10.1080/14656566.2023.2230126]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2954335
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact